BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 2:00 PM EST. The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will ...

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Company Overview - Tango Therapeutics has appointed Malte Peters as the new CEO, succeeding Barbara Weber, who served as CEO until last Thursday [2][3] - Barbara Weber will continue to serve as Executive Chairman and has been instrumental in the company's development since its inception [2][3] Leadership Transition - Malte Peters has a strong background in the pharmaceutical industry, having previously served as Chief R&D Officer at MorphoSys, which is relevant to Tango's future development needs [3] - The leadership change is part of a strategic move as the company prepares to advance its key drug, vopimetostat, which is considered crucial for the company's future [4]

Summary of Tango Therapeutics FY Conference Call Company Overview - **Company**: Tango Therapeutics (NasdaqGM:TNGX) - **Date of Conference**: January 14, 2026 - **New CEO**: Malte Peters, who succeeded Barbara Weber as CEO Key Points and Arguments Leadership Transition - Barbara Weber, the founding CEO, transitioned leadership to Malte Peters, emphasizing the need for a focus on late-phase drug development and regulatory discussions [2][3][29] - Peters has a background in R&D and has been involved with Tango since 2018, ensuring a smooth transition [2][30] Pipeline and Drug Development - Tango is moving from clinical validation to late-phase drug development, focusing on drugs targeting MTAP deletions in cancer [4][6] - **Pipeline Highlights**: - **TNG462**: In dose expansion studies, targeting approximately 60,000 patients annually in the U.S. with MTAP deletions [5][9] - **TNG456**: A blood-brain barrier penetrant molecule entering phase one clinical trials [5][9] - **TNG961**: An HBS1L degrader ready for clinical trials, targeting FOCAT deletion in MTAP-deleted cancers [19] Clinical Milestones for 2026 - Launch a pivotal trial in second-line pancreatic cancer [6][20] - Complete TNG462 RAS inhibitor combination studies [6][20] - Expand knowledge base in lung cancer and other indications [6][20] - Evaluate TNG456 efficacy in glioblastoma [6][20] Competitive Advantages - Received FDA support for pivotal trial protocol and statistical analysis plan [12][8] - Best-in-class potential for TNG462 based on selectivity, potency, and safety profile [8][9] - First company to combine a PRMT5 inhibitor with RAS inhibitors in clinical trials [9] Clinical Data Insights - TNG462 shows a 27% response rate and a median progression-free survival (PFS) of 6.4 months across multiple tumor histologies [10] - Comparison with standard care indicates a potential doubling of median PFS for patients with MTAP deletions [11][12] - A 49% response rate observed in a histology-selective cohort with a median PFS of 9.1 months [17] Strategic Focus - Emphasis on addressing high unmet medical needs in difficult-to-treat cancers [6] - Potential for a chemo-free treatment regimen for pancreatic cancer patients [15] - Commitment to robust data before public disclosure, independent of medical meetings [27] Other Important Content - Discussion on the mechanism of PRMT5 inhibitors and their reliance on MTAP deletion for therapeutic efficacy [22] - Peters' priorities include rapid advancement into late-phase drug development and regulatory readiness [23] - Barbara Weber highlighted the successful transition from a genomic target discovery platform to readiness for pivotal studies [28] This summary encapsulates the critical aspects of Tango Therapeutics' conference call, focusing on leadership changes, pipeline developments, clinical milestones, competitive advantages, and strategic focus.

Pipeline and Clinical Development - Vopimetostat, a PRMT5 inhibitor, is in dose expansion for MTAP-del cancers and dose escalation for RAS-mut pancreatic and lung cancer, including combinations with RAS inhibitors[13] - TNG456, a brain-penetrant PRMT5 inhibitor, is in dose escalation for MTAP-del glioblastoma[13] - TNG961, an HBS1L degrader, has Phase 1 enabled for MTAP/FOCAD-del solid tumors[13] - A pivotal study for vopimetostat monotherapy in 2L MTAP-del pancreatic cancer is planned to start in 2026[23, 37] - Early data from the vopimetostat + RAS(ON) inhibitor clinical study is encouraging, with 30 patients dosed and both combinations well-tolerated[45, 48] Vopimetostat Clinical Data - Vopimetostat monotherapy demonstrated an Overall Response Rate (ORR) of 27% across 16 different histologies and a Disease Control Rate (DCR) of 78%[30] - In 2L pancreatic cancer, vopimetostat showed a median Progression-Free Survival (mPFS) of 7.2 months, more than twice historical Standard of Care (SOC) trials[32, 35] - In a histology-selective cohort, vopimetostat achieved an ORR of 49%, a DCR of 89%, and an mPFS of 9.1 months[50, 53] Financial Status - The company reported a cash balance of $343 million as of December 31, 2025, providing a cash runway into 2028[19, 81] Glioblastoma Focus - TNG456 is being developed for MTAP-del glioblastoma, which represents 45% of GBM cases, or approximately 7,000 patients per year in the US[23]

Compensation and Benefits - The Executive's initial base salary is set at $720,000 per year, subject to periodic review and potential increase by the Board[6]. - The Executive is eligible for an initial target annual incentive compensation of 60% of the Base Salary, which will be determined based on performance objectives[7]. - The Executive will receive a monthly housing allowance of $15,000 gross for the first two years of the Term, once the required visa is obtained[9]. - The Executive will be granted new hire equity awards consisting of 1,650,000 stock options and 350,000 restricted stock units, with specific vesting schedules[11]. - The Option will vest over four years, with 25% vesting on the first anniversary of January 8, 2026, and the remainder vesting in 36 equal monthly installments[11]. Employment Terms - The Executive's employment is "at will," allowing termination by either party at any time for any reason[3]. - The Company may terminate the Executive's employment without Cause at any time, with specific conditions outlined for termination[18]. - The Executive may terminate employment for Good Reason, which includes material changes in title, salary, or location[19]. Termination and Severance - Upon termination, the Executive will receive any earned but unpaid Base Salary and accrued but unused vacation[25]. - The Executive will be deemed to have resigned from all officer and board member positions upon termination of employment[26]. - If the Executive's employment is terminated without Cause, the Company will pay a Severance Amount equal to 12 months of Base Salary plus a prorated Target Bonus[28]. - In the event of termination within the Change in Control Period, the Executive will receive a lump sum of 18 months of Base Salary plus 1.5 times the Target Bonus for the current year plus a Prorated Bonus[33]. - The Company will pay the Prior Year Bonus if the termination occurs after the end of a calendar year and the annual incentive compensation has been approved but not yet paid[34]. - Health insurance contributions will be made for up to 18 months post-termination, subject to the Executive's copayment and COBRA election[34]. - Time-Based Equity Awards will immediately accelerate and become fully vested upon termination within the Change in Control Period[34]. - Payments under the severance agreement will commence within 60 days after the Date of Termination, with specific provisions for tax implications[35]. - Aggregate Payments may be reduced to avoid excise tax under Section 4999 of the Code, ensuring a higher After Tax Amount for the Executive[37]. - The Company will determine if the Executive is a "specified employee" under Section 409A, which may delay certain payments for six months[41]. Reimbursements and Agreements - All reimbursements for in-kind benefits must be provided within specified time frames and cannot affect benefits in other taxable years[42]. - Payments classified as "non-qualified deferred compensation" will only be made upon the Executive's separation from service as defined by the applicable regulations[43]. - The Executive is required to enter into a Restrictive Covenants Agreement, which includes noncompetition and nonsolicitation provisions, as a condition of employment[46]. - The Company will reimburse the Executive for reasonable out-of-pocket expenses incurred in connection with obligations related to litigation and regulatory cooperation[48]. - The Agreement may be amended to comply with Section 409A of the Code without additional cost to either party[44]. - The Executive's eligibility for equity, cash incentive, and severance compensation is considered sufficient consideration for the Restrictive Covenant Agreement[46]. - The Company and the Executive will enter into an Indemnification Agreement covering acts while serving on the Board[53]. Legal and Governing Provisions - The Agreement is governed by the laws of the Commonwealth of Massachusetts[63]. - The Executive's employment will be governed by a Limited Term Employment Agreement until the Effective Date[65]. - The Agreement shall survive the termination of the Executive's employment to effectuate its terms[58]. - The Executive waives the right to a jury trial in any proceeding related to this Agreement[52]. - The Agreement constitutes the entire agreement between the parties and supersedes all prior agreements[54].

Core Viewpoint - Tango Therapeutics announces the retirement of founding CEO Dr. Barbara Weber, who will transition to Executive Chair, while Dr. Malte Peters is appointed as President and CEO, effective immediately [1][2][3] Leadership Transition - Dr. Barbara Weber will support the senior management team and work with Dr. Peters to ensure a smooth transition and continued clinical execution throughout 2026 [2] - Alexis Borisy will move from Board Chair to Lead Independent Director [2] Achievements and Future Direction - Dr. Weber expressed pride in the company's accomplishments over the past eight years, particularly in advancing vopimetostat into its first registrational trial [3] - Dr. Peters brings extensive experience in clinical development and leadership, having previously served as Chief Research and Development Officer at MorphoSys AG and held key positions at Novartis [3] Clinical Milestones - The company has renewed its guidance on anticipated clinical milestones for 2026, including combination trials with vopimetostat and daraxonrasib, as well as vopimetostat and zoldonrasib, with initial safety and efficacy data expected in 2026 [4] - Upcoming pivotal studies include vopimetostat monotherapy for second-line pancreatic cancer and TNG456 monotherapy phase 1/2 trial [6]

Core Insights - Tango Therapeutics, Inc. has appointed Mr. Sung Lee to its Board of Directors, bringing over 20 years of finance leadership experience in the biopharmaceutical and technology sectors [1][2] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision cancer medicines [1] - The company is advancing its lead program, vopimetostat, into registrational studies [2] Leadership Appointment - Mr. Sung Lee's experience includes serving as Executive Vice President and Chief Financial Officer at Cytokinetics since May 2024, and prior roles at Vir Biotechnology, MorphoSys, and Sangamo Therapeutics [2] - He has a strong background in corporate strategy, investor relations, and finance, which will support Tango's late-stage clinical development activities [2] Educational Background - Mr. Lee holds a bachelor's degree in economics from the University of California, Irvine, and a Master of Business Taxation from the University of Southern California [2]

Summary of Key Points from Biotechnology Equity Research Conference Call Industry Overview - The report focuses on the biotechnology sector, specifically highlighting companies with significant potential for growth and upcoming catalysts in 2026. Key Companies and Their Outlook 1. **Dianthus Therapeutics, Inc. (DNTH)** - Market Cap: $1.82 billion - Price Target: $66 - Key catalysts include: - CIDP Phase III interim analysis in Q2 2026 - Initiation of gMG Phase III study in mid-2026 - Phase II MMN topline data in 2H26 - Potential for significant upside based on peak revenue estimates of ~$2 billion across neuromuscular diseases [19][20][24] 2. **Taysha Gene Therapies, Inc. (TSHA)** - Market Cap: $1.50 billion - Price Target: $11 - Focus on pivotal study for TSHA-102 in Rett syndrome with potential for a 6-month interim readout by YE26/1Q27 [26][27] 3. **Tyra Biosciences (TYRA)** - Market Cap: $1.36 billion - Price Target: $32 - Major catalysts include: - Phase III data for achondroplasia in early 2026 - Initial data for IR-NMIBC in 1H26 - Potential to disrupt the market with oral FGFR3 inhibitors [31][35] 4. **Tango Therapeutics, Inc. (TNGX)** - Market Cap: $1.15 billion - Price Target: $14 - Expected to show de-risking data for vopimetostat in combination with RVMD's RAS inhibitors in 2026 [37][40] 5. **ORIC Pharmaceuticals (ORIC)** - Market Cap: $783 million - Price Target: $23 - Key catalysts include dose-optimization data for prostate cancer and validating data from PFE's MEVPRO-1 trial [42][48] 6. **Solid Biosciences (SLDB)** - Market Cap: $463 million - Price Target: $15 - Focus on DMD program with key regulatory feedback expected in 1H26 [49][53] Major Catalysts and Events - **Upcoming Catalysts:** - RARE and MREO Phase III ORBIT final analysis expected in Dec'25/Jan'26 with potential stock movements of +100%/-30% [2] - ALNY, CRSP, and others expected to provide revenue guidance and business plans early in 2026 [1] - Regulatory events including FDA's Rare Disease Day on 2/23/26 [12] - **Drug Launches:** - Expected launches in 2026 include drugs from ALNY, ARWR, KALV, and others targeting various conditions [3] Financial Updates - **Price Target Changes:** - ARWR raised from $67 to $90 - KOD raised from $24 to $39 [6][10] Market Dynamics - **Pricing Stability:** - 2026 net pricing expected to remain stable with current Medicare contracts influencing high gross-to-net (GTN) guidance [12] - **Strategic Interest:** - Potential for M&A activity as companies like ORIC attract interest due to their prostate cancer programs [43] Conclusion - The biotechnology sector is poised for significant developments in 2026, with multiple companies presenting strong investment opportunities based on upcoming catalysts, drug launches, and strategic positioning in the market.

Group 1: Microsoft Corporation - Microsoft Corporation continues to show strong performance in cloud computing, with Azure revenue growth of 35% year-over-year [1] - The company reported a total revenue of $52.9 billion for the last quarter, reflecting a 12% increase compared to the previous year [1] - Microsoft’s focus on AI integration across its products is expected to drive future growth and enhance competitive positioning [1] Group 2: California Resources Corp - California Resources Corp has seen a significant increase in oil production, reporting a 10% rise in output to 130,000 barrels per day [1] - The company’s financial health is improving, with a net income of $150 million for the last quarter, up from $100 million a year earlier [1] - California Resources Corp is actively pursuing sustainability initiatives, aiming to reduce carbon emissions by 25% by 2025 [1] Group 3: Tango Therapeutics Inc - Tango Therapeutics Inc has made advancements in its drug pipeline, with two candidates entering late-stage clinical trials [1] - The company reported a cash position of $200 million, providing a strong runway for ongoing research and development [1] - Partnerships with larger pharmaceutical companies are being explored to enhance the development of its therapies [1]